• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.

    8/15/25 5:01:03 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IGMS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)


    IGM Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.01 per share

    (Title of Class of Securities)


    449585108

    (CUSIP Number)


    Redmile Group, LLC
    Attn: Joshua Garcia, One Letterman Drive Bldg D, Ste D3-300
    San Francisco, CA, 94129
    (415) 489-9980

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    08/14/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    449585108


    1 Name of reporting person

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:
    (1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"). (2) Percent of class is calculated based on 36,593,204 shares of Common Stock outstanding as of July 25, 2025 reported in the Issuer's quarterly report for the quarterly period ended June 30, 2025 on Form 10-Q as filed with the SEC on July 31, 2025 (the "Form 10-Q").


    SCHEDULE 13D

    CUSIP No.
    449585108


    1 Name of reporting person

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:
    (1) The source of funds was working capital of the Redmile Funds. (2) Percent of class is calculated based on 36,593,204 shares of Common Stock outstanding as of July 25, 2025 reported in the Issuer's Form 10-Q.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.01 per share
    (b)Name of Issuer:

    IGM Biosciences, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    3 East Third Avenue, Suite 200, San Mateo, CALIFORNIA , 94401.
    Item 2.Identity and Background
    (a)
    This amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on September 24, 2019 (the "Original Schedule 13D"), as amended by that amendment No. 1 to Schedule 13D filed with the SEC on September 10, 2020, that amendment No. 2 to Schedule 13D filed with the SEC on December 15, 2020, that amendment No. 3 to Schedule 13D filed with the SEC on April 5, 2022, that amendment No. 4 to Schedule 13D filed with the SEC on October 5, 2022, that amendment No. 5 to Schedule 13D filed with the SEC on June 13, 2023, and that amendment No. 6 to Schedule 13D filed with the SEC on June 28, 2023 (hereinafter the Original Schedule 13D and such amendments shall collectively be referred to as the "Prior Schedule 13D"), in each case by Redmile Group, LLC, a Delaware limited liability company ("Redmile"), and Jeremy C. Green, a citizen of the United Kingdom (each, a "Reporting Person"), relating to the Common Stock of IGM Biosciences, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 7, the Prior Schedule 13D is unchanged.
    Item 4.Purpose of Transaction
     
    Item 4 of the Prior Schedule 13D is hereby amended and supplemented in its entirety by adding the following paragraphs prior to the last paragraph of Item 4: The Tender Offer and the Merger On August 14, 2025, pursuant to the terms of the previously announced agreement and plan of merger, dated June 1, 2025 (the "Merger Agreement"), by an among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed its tender offer (the "Offer") to acquire all of the Issuer's issued and outstanding Common Stock and Non-Voting Common Stock (the "Issuer Shares") in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of the CVR Agreement described below (the "Purchase Price"). The Offer was subject to certain conditions, including among others that more than 50% of the Issuer's outstanding Common Stock be validly tendered in the Offer, inclusive of the shares of Common Stock owned by Parent and its affiliates. The Offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). Redmile and the Redmile Funds tendered 100% of their Issuer Shares to Merger Sub by the Offer Closing in exchange for the aggregate Purchase Price. The Issuer Shares tendered by Redmile and the Redmile Funds included (a) 2,952,131 shares of Common Stock, and (b) 7,199,325 shares of Non-Voting Common Stock. On August 14, 2025, the Issuer completed the merger transaction with and into Merger Sub, with the Issuer surviving as a wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement and applicable Delaware law (the "Merger"). At the effective time and date of the Merger (the "Merger Closing"), and without any action on the part of the Issuer stockholders, (a) each Issuer Share (other than those shares owned by (i) Parent, Merger Sub or any other Parent subsidiary after the Offer or (ii) any Issuer stockholders who are entitled to and who properly exercised their appraisal rights under Delaware law) automatically converted into the right to receive cash in the amount of the Offer Price; (b) each Pre-Funded Warrant was cancelled and the holder received the right to a cash amount based on the Offer Price, subject to applicable tax withholding and without interest, less the exercise price per share underlying the Pre-Funded Warrant, plus one CVR per underlying share subject to the terms and conditions of the CVR Agreement described below; (c) each in-the-money Option automatically vested and was cancelled and the holder received the right to a cash amount based on the Offer Price, subject to applicable tax withholding and without interest, less the exercise price per share underlying the Option, plus a CVR per underlying share subject to the terms and conditions of the CVR Agreement described below; and (d) each out-of-the-money Option was cancelled for no consideration. Immediately prior to the Merger Closing, Redmile beneficially owned 667,666 Pre-Funded Warrants, and all of the Options beneficially owned by Redmile were out-of-the-money. Immediately prior to the Offer Closing Time, Redmile beneficially owned 12,712 shares of Common Stock issued pursuant to fully vested RSUs granted to Michael Lee, a managing director of Redmile, in connection with his service as a member of the Issuer's Board of Directors. All of such shares were tendered in the Offer in exchange for the aggregate Purchase Price. Pursuant to the policies of Redmile, Mr. Lee held the Common Stock issued pursuant to the RSUs as a nominee on behalf, and for the sole benefit, of Redmile and its affiliates, and assigned all economic, pecuniary and voting rights in respect of the Common Stock issued pursuant to the RSUs to Redmile. Redmile and Mr. Green each disclaim beneficial ownership of such securities, except to the extent of its or his pecuniary interest in such securities, if any, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities any purpose. In connection with the Merger, Parent, Merger Sub and a rights agent entered into a contingent value rights agreement (the "CVR Agreement"), which provides that each CVR represents a contractual right to receive contingent cash payments equal to: (i) 100% of the amount by which Closing Net Cash (as finally determined pursuant to the Merger Agreement) exceeds $82.0 million, adjusted for any claims Parent reasonably determines to be valid five business days prior to the Merger Closing Date (as defined in the Merger Agreement) and that are not accounted for in such Closing Net Cash; and (ii) 80% of the Net Proceeds (as defined in the CVR Agreement), if any, from any sale, transfer, license or other disposition or grant of rights by Parent or any of its affiliates of all or any part of certain products and patents of the Issuer that occurs within the period beginning on the Merger Closing Date and ending on the first anniversary thereof. The foregoing descriptions of the Merger Agreement and the CVR Agreement do not purport to be complete and are qualified in their entirety by reference to the Merger Agreement and Form of CVR Agreement, copies of which are filed as Exhibit 2.1 and Exhibit 10.1, respectively, in the Issuer's Form 8-K filed on July 1, 2025 and are incorporated herein by reference. Resignation of Mike Lee from the Board of Directors Pursuant to the terms of the Merger Agreement, Michael Lee resigned from the Issuer's Board of Directors effective immediately prior to the Merger Closing.
    Item 5.Interest in Securities of the Issuer
    (a)
    Redmile: (1) Aggregate Number of Common Stock Beneficially Owned: 0 (2) Aggregate Percentage of Common Stock Beneficially Owned: 0.0% Jeremy C. Green: (1) Aggregate Number of Common Stock Beneficially Owned: 0 (2) Aggregate Percentage of Common Stock Beneficially Owned: 0.0%
    (b)
    Redmile: (1) Sole Voting Power: 0 (2) Shared Voting Power: 0 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 0 Jeremy C. Green: (1) Sole Voting Power: 0 (2) Shared Voting Power: 0 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 0
    (c)
    See the response to Item 4. Except as disclosed in Item 4, no reportable transactions were effected by any Reporting Persons during the past sixty days.
    (e)
    As of August 14, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the class of securities.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The information in Item 4 is incorporated herein by reference.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:08/15/2025
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:08/15/2025
    Get the next $IGMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGMS

    DatePrice TargetRatingAnalyst
    1/10/2025$21.00 → $2.00Outperform → Market Perform
    BMO Capital Markets
    1/10/2025$12.00 → $2.00Equal-Weight → Underweight
    Morgan Stanley
    1/10/2025$27.00 → $2.50Buy → Hold
    Stifel
    1/10/2025$20.00 → $1.50Outperform → Sector Perform
    RBC Capital Mkts
    1/10/2025Buy → Neutral
    Guggenheim
    12/6/2024$21.00Outperform
    BMO Capital Markets
    10/1/2024$12.00 → $9.00Neutral → Underweight
    JP Morgan
    10/1/2024$24.00 → $12.00Buy → Hold
    Truist
    More analyst ratings

    $IGMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Former 10% owner and director Baker Bros. Advisors Lp

    4 - IGM Biosciences, Inc. (0001496323) (Issuer)

    8/18/25 5:39:42 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Redmile Group, Llc returned 2,964,843 shares to the company (SEC Form 4)

    4 - IGM Biosciences, Inc. (0001496323) (Issuer)

    8/15/25 5:00:13 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hambleton Julie returned 2,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - IGM Biosciences, Inc. (0001496323) (Issuer)

    8/14/25 8:52:50 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right

    MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and (ii) 80% of any net proceeds received within one year fol

    7/1/25 8:58:31 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

    – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases.    "Interim data

    1/9/25 1:00:00 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

    – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

    11/8/24 7:00:00 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IGM Biosciences downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded IGM Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $21.00 previously

    1/10/25 8:15:47 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded IGM Biosciences from Equal-Weight to Underweight and set a new price target of $2.00 from $12.00 previously

    1/10/25 8:15:47 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences downgraded by Stifel with a new price target

    Stifel downgraded IGM Biosciences from Buy to Hold and set a new price target of $2.50 from $27.00 previously

    1/10/25 8:15:16 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    SEC Filings

    View All

    SEC Form 15-12G filed by IGM Biosciences Inc.

    15-12G - IGM Biosciences, Inc. (0001496323) (Filer)

    8/25/25 9:00:14 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.

    SCHEDULE 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)

    8/18/25 5:52:19 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.

    SCHEDULE 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)

    8/15/25 5:01:03 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Baker Bros. Advisors Lp bought $3,425,569 worth of shares (395,317 units at $8.67) (SEC Form 4)

    4 - IGM Biosciences, Inc. (0001496323) (Issuer)

    3/28/24 7:04:05 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baker Bros. Advisors Lp bought $3,431,464 worth of shares (532,693 units at $6.44) (SEC Form 4)

    4 - IGM Biosciences, Inc. (0001496323) (Issuer)

    12/15/23 5:32:35 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    Leadership Updates

    Live Leadership Updates

    View All

    Medivir Appoints Jens Lindberg as Chief Executive Officer

    STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO. Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global responsibilities as well as development of phase 2/3 programs to maximise the commercial value for o

    10/25/21 2:45:00 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units

    – John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM's platform technology to create and develop novel IgM and IgA antibodies to ad

    10/11/21 4:05:00 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Medivir appoints Malene Jensen as VP Clinical Development

    STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team. Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm. "We are pleased to welcome Malene and her vast cl

    7/1/21 11:54:00 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    Financials

    Live finance-specific insights

    View All

    IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

    – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

    11/8/24 7:00:00 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

    – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development

    9/30/24 4:01:00 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

    – Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical

    8/14/24 7:00:00 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

    SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

    11/14/24 1:22:39 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

    SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

    11/12/24 10:32:10 AM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

    SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

    8/2/24 6:41:27 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care